Successful combination chemotherapy for metastatic inflammatory myofibroblastic tumor: A case report

被引:6
作者
Inadomi, Kyoko [1 ]
Kumagai, Hozumi [1 ]
Takayoshi, Kotoe [1 ]
Ariyama, Hiroshi [1 ]
Kusaba, Hitoshi [1 ]
Nishie, Akihiro [2 ]
Yamamoto, Hidetaka [3 ,4 ]
Takase, Ken [5 ]
Tanaka, Mamoru [1 ]
Sagara, Kosuke [1 ]
Okumura, Yuta [1 ]
Nio, Kenta [1 ]
Nakano, Michitaka [1 ]
Arita, Shuji [1 ]
Oda, Yoshinao [3 ,4 ]
Akashi, Koichi [1 ]
Baba, Eishi [6 ]
机构
[1] Kyushu Univ Hosp, Dept Hematol & Oncol, Fukuoka, Japan
[2] Kyushu Univ, Grad Sch Med Sci, Dept Clin Radiol, Fukuoka 8128582, Japan
[3] Kyushu Univ, Grad Sch Med Sci, Dept Anat Pathol, Fukuoka 8128582, Japan
[4] Kyushu Univ, Grad Sch Med Sci, Dept Pathol Sci, Fukuoka 8128582, Japan
[5] Natl Hosp Org, Kyushu Med Ctr, Dept Hematol, Fukuoka 8100065, Japan
[6] Kyushu Univ, Fac Med Sci, Dept Comprehens Clin Oncol, Fukuoka 8128582, Japan
关键词
inflammatory pseudotumor; metastatic inflammatory myofibroblastic tumor; chemotherapy; anaplastic lymphoma kinase rearrangement negative; PSEUDOTUMOR; THERAPY; MDM2;
D O I
10.3892/ol.2015.3708
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A 64-year-old male presented with increased abdominal fullness and fever. Radiological examination revealed moderate ascites, a tumor with a diameter of 12.5 cm in the mesenteric region, as well as multiple tumors in the thoracic and abdominal para-aortic regions and in the left supraclavicular regions. Pathohistological findings of the biopsy specimen revealed atypical spindle cells accompanied by infiltration of lymphocytes. The plasmacytes were positive for CD68, murine double minute 2 and S-100, while they were negative for a-smooth muscle actin, cyclin-dependent kinase 4 and anaplastic lymphoma kinase. Clinically, the patient presented systemic symptoms and laboratory results indicated an elevation in the inflammatory response, while the CT and MRI findings were consistent with an inflammatory myofibroblastic tumor (IMT). Based on the clinical and histological findings, the patient was diagnosed with IMT. In total, 4 cycles of combination chemotherapy with doxorubicin and ifosfamide were administered. Tumor size reduction by 50% was achieved subsequent to the 4th chemotherapy cycle. In conclusion, successful control of this rare metastatic IMT was achieved by systemic chemotherapy.
引用
收藏
页码:2981 / 2985
页数:5
相关论文
共 20 条
  • [11] Successful Treatment of an Unresectable Inflammatory Myofibroblastic Tumor of the Frontal Bone Using a Cyclooxygenase-2 Inhibitor and Methotrexate
    Kusunoki-Nakamoto, Fumiko
    Matsukawa, Takashi
    Tanaka, Masaki
    Miyagawa, Toji
    Yamamoto, Tomotaka
    Shimizu, Jun
    Ikemura, Masako
    Shibahara, Junji
    Tsuji, Shoji
    [J]. INTERNAL MEDICINE, 2013, 52 (05) : 623 - 628
  • [12] TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors
    Lawrence, B
    Perez-Atayde, A
    Hibbard, MK
    Rubin, BP
    Dal Cin, P
    Pinkus, JL
    Pinkus, GS
    Xiao, S
    Yi, ES
    Fletcher, CDM
    Fletcher, JA
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2000, 157 (02) : 377 - 384
  • [13] Dedifferentiated Liposarcoma With Inflammatory Myofibroblastic Tumor-like Features
    Lucas, David R.
    Shukla, Abhishek
    Thomas, Dafydd G.
    Patel, Rajiv M.
    Kubat, Anthony J.
    McHugh, Jonathan B.
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2010, 34 (06) : 844 - 851
  • [14] ALKoma: A Cancer Subtype with a Shared Target
    Mano, Hiroyuki
    [J]. CANCER DISCOVERY, 2012, 2 (06) : 495 - 502
  • [15] INFLAMMATORY FIBROSARCOMA OF THE MESENTERY AND RETROPERITONEUM - A TUMOR CLOSELY SIMULATING INFLAMMATORY PSEUDOTUMOR
    MEIS, JM
    ENZINGER, FM
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1991, 15 (12) : 1146 - 1156
  • [16] National Cancer Institute, 1998, CANC THER EV PROGR C
  • [17] Regression of nonresectable inflammatory myofibroblastic tumours after treatment with nonsteroidal anti-inflammatory drugs
    Przkora, R
    Bolder, U
    Schwarz, S
    Jauch, KW
    Spes, J
    Andreesen, R
    Mackensen, A
    [J]. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2004, 34 (04) : 320 - 321
  • [18] Trecate G, 2010, PEDIAT BLOOD CANC, V54, P483
  • [19] U.S. Department of Health and Human Services NIoH National Cancer Institute, 2009, Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0
  • [20] p53 mutation and MDM2 amplification in inflammatory myofibroblastic tumours
    Yamamoto, H
    Oda, Y
    Saito, T
    Sakamoto, A
    Miyajima, K
    Tamiya, S
    Tsuneyoshi, M
    [J]. HISTOPATHOLOGY, 2003, 42 (05) : 431 - 439